Issue 4/2022
Spotlight: Heart Failure
Content (12 Articles)
Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
Marc Ulrich Becher, Mahmoud Balata, Michaela Hesse, Fabian Draht, Christian Zachoval, Birgitta Weltermann, Ralf Westenfeld, Martin Neukirchen, Roman Pfister, Thomas Standl, Lukas Radbruch, Georg Nickenig
Serum potassium dynamics during acute heart failure hospitalization
Pedro Caravaca Perez, José R. González-Juanatey, Jorge Nuche, Laura Morán Fernández, David Lora Pablos, Jesús Alvarez-García, Ramón Bascompte Claret, Manuel Martínez Selles, Rafael Vázquez García, Luis Martínez Dolz, Marta Cobo-Marcos, Domingo Pascual Figal, Maria G. Crespo-Leiro, Julio Nuñez Villota, Juan Cinca Cuscullola, Juan F. Delgado
Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial
Pieter Martens, João Pedro Ferreira, John Vincent, Paula Abreu, Martijn Busselen, Wilfried Mullens, Wilson W. H. Tang, Michael Böhm, Bertram Pitt, Faiez Zannad, Patrick Rossignol
Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart
Andreas J. Rieth, Manuel J. Richter, Khodr Tello, Henning Gall, Hossein A. Ghofrani, Stefan Guth, Christoph B. Wiedenroth, Werner Seeger, Steffen D. Kriechbaum, Veselin Mitrovic, P. Christian Schulze, Christian W. Hamm
Establishing a cardiac training group for patients with heart failure: the “HIP-in-Würzburg” study
Gülmisal Güder, Joana Wilkesmann, Nina Scholz, Robert Leppich, Peter Düking, Billy Sperlich, Christian Rost, Stefan Frantz, Caroline Morbach, Floran Sahiti, Ulrich Stefenelli, Margret Breunig, Stefan Störk
Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction
Jan-Per Wenzel, Ramona Bei der Kellen, Christina Magnussen, Stefan Blankenberg, Benedikt Schrage, Renate Schnabel, Julius Nikorowitsch
Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis
Tobias Täger, Lutz Frankenstein, Dan Atar, Stefan Agewall, Norbert Frey, Morten Grundtvig, Andrew L. Clark, John G. F. Cleland, Hanna Fröhlich
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF
Thor Ueland, Lars Gullestad, Lei Kou, James B. Young, Marc A. Pfeffer, Dirk Jan van Veldhuisen, Karl Swedberg, John J. V. Mcmurray, Akshay S. Desai, Inderjit S. Anand, Pål Aukrust
Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT
João Pedro Ferreira, Patrick Rossignol, Brian L. Claggett, Scott D. Solomon, Bertram Pitt, Marc Pfeffer, Faiez Zannad
The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes
Bochra Zareini, Paul Blanche, Anders Holt, Mariam Elmegaard Malik, Christian Selmer, Gunnar Gislason, Søren Lund Kristensen, Lars Køber, Christian Torp-Pedersen, Morten Schou, Morten Lamberts
SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoring
Klara Kirschbaum, Mariuca Vasa-Nicotera, Andreas Michael Zeiher, Sebastian Cremer
Correction to: Predicting survival in heart failure: a risk score based on machine-learning and change point algorithm
Wonse Kim, Jin Joo Park, Hae-Young Lee, Kye Hun Kim, Byung-Su Yoo, Seok-Min Kang, Sang Hong Baek, Eun-Seok Jeon, Jae-Joong Kim, Myeong-Chan Cho, Shung Chull Chae, Byung-Hee Oh, Woong Kook, Dong-Ju Choi